195940 - HK inno.N Corporation

195940 Summary

Biopharma

Stock Price & Overview

₩42,050 +300 (+0.72%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩42,050 ≈ US$30 · Market cap ₩1.2tn (≈ $851m)

195940 Financial Statements

Breakdown ₩ tn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Total Revenue	1.06	0.90	0.83	0.85	0.77	0.60	0.14
Cost of Revenue	0.58	0.46	0.45	0.50	0.45	0.27	0.00
Gross Profit	0.49	0.44	0.38	0.35	0.32	0.32	0.14
Selling, General & Administrative	0.38	0.35	0.31	0.30	0.27	0.24	0.00
Operating Income	0.11	0.09	0.07	0.05	0.05	0.09	0.14
Finance Income	0.01	0.01	0.01	0.01	0.00	0.00	0.00
Finance Costs	0.02	0.02	0.02	0.02	0.02	0.03	0.03
Pretax Income	0.09	0.07	0.05	0.04	0.03	0.05	0.11
Income Tax Expense	0.02	0.01	-0.00	-0.00	0.00	0.03	0.00
Net Income	0.08	0.06	0.05	0.04	0.02	0.03	0.10
Total Comprehensive Income	0.09	0.05	0.04	0.04	0.02	0.03	0.10

Breakdown ₩ tn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Total Assets	2.10	1.89	1.85	1.80	1.84	1.61	1.32
Current Assets	0.49	0.39	0.43	0.41	0.46	0.23	0.00
Cash & Cash Equivalents	0.09	0.05	0.11	0.11	0.09	0.05	0.00
Inventories	0.17	0.18	0.14	0.13	0.11	0.08	0.00
Trade Receivables	0.14	0.12	0.15	0.13	0.12	0.10	0.00
Non-current Assets	1.61	1.50	1.42	1.39	1.38	1.38	1.32
Property, Plant & Equipment	0.40	0.38	0.28	0.26	0.25	0.26	0.00
Intangible Assets	1.07	1.07	1.08	1.09	1.09	1.07	0.00
Total Liabilities	0.77	0.64	0.64	0.64	0.69	0.87	0.53
Current Liabilities	0.59	0.46	0.60	0.43	0.41	0.31	0.06
Non-current Liabilities	0.18	0.17	0.05	0.21	0.27	0.56	0.47
Total Equity	1.33	1.25	1.20	1.16	1.15	0.74	0.79
Share Capital	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Retained Earnings	0.27	0.21	0.11	0.09	0.05	0.03	0.08

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Cash from Operating Activities	162.0	105.9	83.0	58.6	26.8	54.1	140.4
Cash from Investing Activities	-171.4	-130.0	-34.0	67.2	-167.1	15.3	0.0
Purchase of Property, Plant & Equipment	74.5	116.8	35.8	20.3	24.1	93.9	0.0
Cash from Financing Activities	55.5	-38.3	-51.9	-102.5	176.0	-78.2	-140.6
Dividends Paid	9.9	5.7	5.2	5.3	0.0	0.0	—
Net Change in Cash	46.1	-62.4	-2.9	23.3	35.7	-8.7	-0.2

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	267.2	258.7	291.9	260.8	263.1	247.4	235.8	229.5	219.3	212.6
Cost of Revenue	147.8	141.5	150.7	142.1	150.0	132.7	121.9	124.2	110.8	105.2
Gross Profit	119.4	117.2	141.2	118.7	113.1	114.6	113.9	105.3	108.5	107.4
Selling, General & Administrative	89.4	84.0	101.1	92.9	93.6	89.2	89.5	83.0	84.2	90.1
Operating Income	30.0	33.2	40.1	25.9	19.5	25.4	24.4	22.2	24.3	17.3
Finance Income	2.6	3.8	4.4	1.1	0.9	1.4	2.4	1.2	0.8	1.4
Finance Costs	4.8	4.5	5.2	3.9	5.9	5.0	4.0	4.8	3.2	4.7
Pretax Income	23.1	31.1	33.5	22.7	14.2	20.8	18.8	17.9	21.7	13.3
Income Tax Expense	9.4	5.1	5.9	4.2	2.2	3.4	-0.4	3.4	4.3	2.8
Net Income	13.7	25.9	27.7	18.6	12.0	17.4	19.2	14.5	17.4	10.5
Total Comprehensive Income	13.3	20.6	34.3	20.9	14.9	16.9	12.8	15.6	16.3	8.6

Breakdown ₩ tn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	2.02	2.07	2.10	2.17	1.94	1.92	1.89	1.87	1.88	1.82
Current Assets	0.44	0.46	0.49	0.63	0.40	0.40	0.39	0.41	0.45	0.40
Cash & Cash Equivalents	0.07	0.06	0.09	0.13	0.05	0.04	0.05	0.07	0.09	0.05
Inventories	0.17	0.17	0.17	0.31	0.17	0.18	0.18	0.18	0.19	0.17
Trade Receivables	0.14	0.14	0.14	0.13	0.13	0.13	0.12	0.12	0.12	0.14
Non-current Assets	1.58	1.61	1.61	1.54	1.54	1.52	1.50	1.46	1.43	1.42
Property, Plant & Equipment	0.40	0.40	0.40	0.41	0.41	0.40	0.38	0.33	0.30	0.29
Intangible Assets	1.07	1.07	1.07	1.07	1.07	1.07	1.07	1.08	1.08	1.07
Total Liabilities	0.67	0.73	0.77	0.87	0.67	0.67	0.64	0.63	0.66	0.62
Current Liabilities	0.49	0.55	0.59	0.65	0.49	0.49	0.46	0.60	0.63	0.57
Non-current Liabilities	0.18	0.18	0.18	0.23	0.18	0.18	0.17	0.03	0.03	0.05
Total Equity	1.35	1.34	1.33	1.29	1.27	1.26	1.25	1.24	1.22	1.21
Share Capital	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Retained Earnings	0.31	0.29	0.27	0.25	0.23	0.22	0.21	0.19	0.18	0.16

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	42.6	15.9	51.0	38.0	41.8	31.3	38.8	31.5	33.1	2.5
Cash from Investing Activities	33.6	-19.8	-101.0	-8.4	-35.5	-26.6	-56.9	-29.3	-23.1	-20.7
Purchase of Property, Plant & Equipment	4.6	4.9	8.6	12.2	27.1	26.7	54.4	27.9	16.6	17.9
Cash from Financing Activities	-68.5	-27.1	13.3	50.6	-2.7	-5.6	-6.1	-26.0	28.8	-34.9
Dividends Paid	—	—	0.0	0.0	—	—	0.0	0.0	—	—
Net Change in Cash	7.7	-30.9	-36.8	80.1	3.7	-0.9	-24.3	-23.8	38.9	-53.2

Separate / parent-only (OFS) — this company files no consolidated statements, from DART. 7 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

195940 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	1,063.2	+18.5%	+7.9%	+12.2%	—
Operating income	110.9	+25.7%	+28.3%	+5.0%	—
Net income	75.7	+22.9%	+25.7%	+22.1%	—
EPS	₩2,672	+22.9%	+25.7%	+22.1%	—
Operating cash flow	162.0	+53.0%	+40.4%	+24.5%	—
Shareholders' equity	1,328.4	+6.2%	+4.5%	+12.3%	—

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

195940 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	45.9%	48.5%	45.4%	41.3%	41.3%	54.1%
Operating margin	10.4%	9.8%	8.0%	6.2%	6.5%	14.5%
Net margin	7.1%	6.9%	5.7%	4.5%	3.2%	4.7%
Return on equity	5.9%	5.0%	4.0%	3.3%	2.6%	3.6%
Return on assets	3.8%	3.3%	2.6%	2.1%	1.4%	1.9%
Operating cash flow / revenue	15.2%	11.8%	10.0%	6.9%	3.5%	9.0%
Capex / revenue	7.0%	13.0%	4.3%	2.4%	3.1%	15.7%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 195940

Symbol	Last Price
006280GC Biopharma Corp.	₩127,600 +0.5%
950160Kolon Tissue Gene, Inc.	₩17,100 +1.1%
039200Oscotec, Inc.	₩36,600 +1.9%
069620Daewoong Pharma	₩116,100 +1.1%
290650L & C BIO Co., Ltd.	₩47,900 -1.4%
127120JS Link	₩33,600 +12.4%
475830Orum Therapeutics, Inc.	₩55,900 +2.6%
003090Daewoong Co., Ltd.	₩16,860 -2.0%
086450Dong Kook Pharmaceutical Co., Ltd.	₩21,600 -0.9%
185750Chong Kun Dang Pharmaceutical Corp.	₩68,000 -0.3%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.